CompletedNot Applicable

Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy

France75 participantsStarted 2013-01-08

Plain-language summary

Impact of screening nodes mediastinal by PET, at different times of the management of cancer disease, remain unclear. Benefits of combined PET and puncture with echoendoscopy for the diagnosis subsequent therapeutic management should be evaluated in these different contexts. We would like to demonstrate the clinical utility of this association to replace more invasive diagnostic procedures and to assess the impact of the puncture on a possible modification of the therapeutic management. It is a single center prospective diagnostic assessment

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Any patients who have had PET showing one or more hypermetabolic lymphadenopathy in middle mediastinum and/or lower and/or posterior, and requiring diagnostic certainty for support.
✓. PET scans performed in these particulars :
✓. PET, the result is positive :
✓. Patient with indication of diagnostic procedure surgically (whether realized or not)
✓. Lymph node(s) available(s) puncture by EUS esophageal, so for a technically feasible for esophageal puncture (without vascular recusants structures)
✓. Age ≥ 18 years.
✓. PET scan performed within 6 weeks before EUS
✓. Platelets ≥ 70 000/mm3; TP ≥ 60%.

What they're measuring

Sensitivity of Endoscopic Ultrasound-guided (EUS-guided) Puncture

Timeframe: 12 months

Trial details

NCT IDNCT01892501

SponsorInstitut Bergonié

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10-10

Results submitted2020-12-14

View on ClinicalTrials.gov More Hypermetabolic Lymphadenopathy Mediastinum Lower, Posterior and Middle, Detected by PET-CT With 18F-FDG (PET) trials